Perimenopause Assessment: Beyond Blood Tests

A single FSH blood test is an unreliable way to confirm perimenopause. Hormone levels can fluctuate significantly within a single day during the transition - some research suggests variability of 30-40% or more, making any point-in-time measurement a snapshot of a moving target. This is why clinicians and researchers are increasingly turning to symptom-based assessment tools, longitudinal tracking, and multi-modal approaches.

Here is a practical review of the tools available today, their strengths and limitations, and where the field is heading.

Why blood tests fall short

The traditional approach to confirming perimenopause involves measuring FSH (follicle-stimulating hormone) and estradiol levels. The problem: during perimenopause, these hormones do not decline steadily. They oscillate erratically, sometimes showing "normal" premenopausal levels one week and elevated levels the next.

The 2022 NICE guidelines (UK National Institute for Health and Care Excellence) explicitly recommend against using FSH testing to diagnose perimenopause in women over 45, stating that diagnosis should be based on symptoms. The North American Menopause Society (NAMS) has taken a similar position, noting that hormone testing is unnecessary for most women with typical perimenopausal symptoms.

Current validated assessment tools

Menopause Rating Scale (MRS)

Developed in the 1990s and validated across multiple populations, the MRS is an 11-item self-administered questionnaire covering three domains: somatic, psychological, and urogenital symptoms. Each item is rated on a 5-point severity scale.

• Strengths: Well-validated, available in 27 languages, free to use, quick to administer (5 minutes)
• Limitations: Does not capture cognitive symptoms well, provides a point-in-time snapshot only, and may not distinguish perimenopause from other conditions

Greene Climacteric Scale

The Greene Scale includes 21 items across psychological (anxiety and depression subscales), somatic, and vasomotor domains. Published in 1998, it remains one of the most widely used tools in menopause research.

• Strengths: Strong psychometric validation, widely used in clinical trials, separates anxiety from depression symptoms
• Limitations: Developed before cognitive symptoms were well understood in this context, no urogenital assessment, designed for cross-sectional rather than longitudinal use

MQ6 (Menopause Questionnaire-6)

A newer, abbreviated tool designed for rapid clinical screening. The MQ6 uses just 6 items to identify women who may benefit from further evaluation. It was developed to address a key barrier: the limited time available in primary care consultations.

• Strengths: Takes under 2 minutes, designed for primary care workflow, high sensitivity as a screening tool
• Limitations: Too brief for comprehensive assessment, limited validation data compared to established scales, not designed for monitoring change over time

Peri-SS (Perimenopause Symptom Screener)

One of the newest tools, the Peri-SS was specifically designed for the perimenopausal transition rather than menopause broadly. It includes items that address the fluctuating, unpredictable nature of perimenopausal symptoms and captures cognitive and mood symptoms more comprehensively.

• Strengths: Perimenopause-specific, captures symptom variability, includes cognitive and mood domains, developed using modern psychometric methods
• Limitations: Relatively new with limited real-world validation, not yet widely adopted in clinical practice

Why longitudinal tracking changes the picture

The STRAW+10 staging system, the current gold standard for classifying reproductive aging, is itself based on longitudinal observation. It defines stages by changes in menstrual cycle patterns and symptoms over time, not by any single measurement.

This points to a fundamental gap in clinical practice: the tools we use for assessment are cross-sectional, but the condition we are assessing is longitudinal. Bridging this gap requires approaches that:

• Capture symptoms repeatedly over weeks and months, not just at an annual visit
• Track trajectories rather than snapshots
• Identify patterns that may not be apparent in a single assessment
• Generate structured data that can be shared with clinicians

Research from the SWAN study (Study of Women's Health Across the Nation) demonstrated that symptom trajectories vary widely among women, with some experiencing rapid onset and resolution, others showing gradual escalation, and still others cycling through recurring episodes. Understanding which trajectory a patient is on requires repeated measurement.

Multi-modal approaches: what is emerging

The most promising developments in perimenopause assessment combine multiple data streams:

Symptom tracking plus cognitive assessment

Cognitive changes are among the most distressing and frequently missed perimenopausal symptoms. Tools that combine symptom questionnaires with objective cognitive testing (processing speed, verbal memory, executive function) may provide a more complete clinical picture.

Biomarker integration

While single blood draws are unreliable, emerging approaches use multiple biomarker measurements over time, or combine biomarker data with symptom data to create composite assessments. Anti-Mullerian Hormone (AMH), while not a perimenopause diagnostic, may provide useful context about reproductive stage when combined with clinical data.

Digital phenotyping

Wearable devices and smartphone-based assessments can passively capture sleep patterns, activity levels, and physiological markers. Combined with active symptom reporting, these data streams may enable continuous, low-burden monitoring that captures the variability that defines perimenopause.

Implications for clinical practice

For clinicians evaluating patients who may be in perimenopause, the current evidence suggests:

1. Symptom assessment should be the primary diagnostic approach for women over 45 with typical symptoms (NICE, NAMS guidelines)
2. Use validated tools rather than informal symptom checklists. The MRS or Greene Scale take only minutes and provide a quantifiable baseline
3. Request or recommend longitudinal tracking. Patients who bring structured symptom data to appointments enable better clinical decisions than those who rely on recall
4. Consider cognitive assessment when patients report brain fog, word-finding difficulty, or concentration problems, both to quantify impact and to distinguish from other causes
5. Reserve blood tests for specific clinical questions: ruling out thyroid dysfunction, evaluating early menopause (under 45), or monitoring treatment response

The bottom line

The assessment tools available today are useful but incomplete. They capture a snapshot of a dynamic process. The gap between what these tools measure and what clinicians need to know is best filled by longitudinal, multi-modal approaches that track change over time across multiple symptom domains.

As the field evolves, expect assessment to shift from "where is this patient right now" to "what trajectory is this patient on, and how is it responding to intervention."